<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859716</url>
  </required_header>
  <id_info>
    <org_study_id>ACE393-103</org_study_id>
    <secondary_id>BB013742</secondary_id>
    <nct_id>NCT00859716</nct_id>
  </id_info>
  <brief_title>ACE393-103 Vaccination Challenge Study</brief_title>
  <acronym>ACE393-103VC</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of ACE393 to Determine Efficacy Against the Symptoms of Moderate to Severe Campylobacter Jejuni Infection in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TD Vaccines A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SNBL Clinical Pharmacology Center, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SGS U.S. Testing Company Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fulcrum Pharma (Europe) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TD Vaccines A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ACE393 vaccination can protect against
      Campylobacteriosis in a challenge model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double blind, parallel group, placebo controlled study, in which
      subjects, with no evidence of prior C.jejuni infections or immunity, will be vaccinated with
      ACE393, a protein sub-unit vaccine, or placebo, and then subsequently challenged with
      C.jejuni. The study will include vaccination of approximately 72 subjects, with the aim of
      challenging a total of 60 subjects. ACE393 or placebo will be administered twice by
      intramuscular injection on an outpatient basis, three weeks apart and then the subjects will
      be challenged three weeks later with C.jejuni. During the inpatient monitoring period,
      volunteers will be evaluated daily for safety, clinical signs and symptoms of disease and
      stool microbiology). Criteria for early institution of oral hydration, intravenous fluids,
      serum electrolyte monitoring, blood cultures, and/or antibiotics are predefined. All
      volunteers will receive antibiotic therapy 6 days after challenge (unless treated early).
      Discharge criteria are predefined. Post-discharge follow-up will further monitor safety,
      confirm C .jejuni eradication after antibiotic therapy, and assess immunologic response.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Moderate or Severe Diarrhea</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Total (individual) stool number (grade 3-5 stools, diarrheal episodes only)</measure>
    <time_frame>20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Total (individual) stool volume (grade 3-5 stools, diarrheal episodes only)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum stool number and volume in a 24 hr period (grade 3-5 stools, diarrheal episodes only)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe diarrhea</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Campylobacter Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccination with ACE393 followed by challenge with campylobacter jejuni</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaccination followed by challenge with campylobacter jejuni</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE393</intervention_name>
    <description>ACE393 250 micrograms as intra muscular injection at day 0 and day 21</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Campylobacter jejuni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo vaccine</intervention_name>
    <description>Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Campylobacter jejuni</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (selected):

          -  Male or female between 18 and 50 years of age.

          -  General good health, without significant medical illness, abnormal physical
             examination findings or clinical laboratory abnormalities as determined by the
             principal investigator or the principal investigator in consultation with the medical
             monitor and sponsor.

          -  Negative serum pregnancy test at screening.

        Exclusion Criteria (selected):

          -  Immunosuppressive illness or clinically significant IgA deficiency.

          -  Positive serology results for HIV, HBsAg, or HCV antibodies.

          -  Evidence of inflammatory arthritis on examination and/or HLA-B27 positive.

          -  Allergy or prior intolerance to selected antibiotics (specified in the protocol)

          -  Fewer than 3 stools per week or more than 3 stools per day as the usual frequency; or
             passing of loose or liquid stools other than on an occasional basis.

          -  History of diarrhea.

          -  Stool culture positive for Campylobacter, other bacterial enteropathogens and
             intestinal parasites.

          -  History of microbiologically confirmed Campylobacter infection.

          -  History of vaccination for or ingestion of Campylobacter.

          -  Immunologic evidence of Campylobacter exposure

          -  Serologic evidence of prior Campylobacter infection.

          -  Cell mediated immune response evidence of prior Campylobacter infection.

          -  Fever within 48 hours preceding challenge.

          -  Presence of any signs or symptoms indicative of active infection.

          -  Diarrhea occurring in the 7 days prior to challenge.

          -  Stool culture positive for Campylobacter, other bacterial enteric pathogens or
             intestinal parasites.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Al-Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shin Nippon Biomedical Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shin Nippon Biomedical Laboratories</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ingelise Saunders/CEO</name_title>
    <organization>ACE BioSciences A/S</organization>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Traveler's Diarrhea</keyword>
  <keyword>Campylobacter jejuni</keyword>
  <keyword>C. jejuni</keyword>
  <keyword>Campylobacter</keyword>
  <keyword>Campy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Campylobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

